Browsing Tag
Alzheimer’s Disease
56 posts
Novo Nordisk’s Alzheimer’s treatment hopes crash as semaglutide fails to slow cognitive decline
Novo Nordisk’s GLP-1 pill failed in Alzheimer’s trials, raising questions on neurology diversification. Read what this means for its pipeline and stock.
Can GLP‑1 drugs tackle Alzheimer’s? Novo Nordisk’s setback raises doubts
Can Novo Nordisk challenge Eli Lilly’s GLP-1 lead with Alzheimer’s data? A crucial trial may redefine the future of semaglutide and reshape investor sentiment.
Breakthrough Parkinson’s research: Annovis says buntanetap improved cognition in patients with amyloid co-pathology
Discover why new biomarker data suggests amyloid co-pathology may accelerate cognitive decline in Parkinson’s and how buntanetap could help change treatment planning.
Leqembi UK approval: BioArctic, Eisai win MHRA nod for once-monthly Alzheimer’s treatment
BioArctic’s Leqembi now approved for monthly IV use in UK Alzheimer’s patients. Find out what this means for long-term treatment worldwide.
Vyepti and Rexulti power Lundbeck (CPH: LUN) to raise 2025 guidance after 22% adjusted EBITDA surge
Lundbeck lifts 2025 guidance as Vyepti and Rexulti drive 22% EBITDA growth. Explore the neuroscience-focused strategy powering its latest earnings surge.
Nexalin Technology unveils breakthrough Alzheimer’s study validating non-drug Gen-2 SYNC brain stimulation
Find out how Nexalin’s Gen-2 SYNC device improved cognition in Alzheimer’s patients with non-drug 40 Hz brain stimulation.
ExQor Technologies moves closer to clinical trials with brain regenerative medicine for Alzheimer’s disease
ExQor Technologies advances toward clinical trials with a brain regenerative platform that could reverse Alzheimer’s damage and transform dementia care.
Eli Lilly wins European approval for Kisunla, a new Alzheimer’s treatment that targets early symptomatic stages
Eli Lilly wins EU approval for Kisunla, a once-monthly Alzheimer’s therapy that slows decline and reshapes Europe’s treatment landscape.
Lighthouse Pharmaceuticals secures $49.2mn NIA grant to advance Phase 2 trial targeting P. gingivalis-positive Alzheimer’s disease
Lighthouse Pharmaceuticals wins $49.2mn NIA grant to trial LHP588, a microbial-targeted Alzheimer’s therapy. Discover its impact on research and patients.
Why Alzheimer’s partnerships with Roche, BMS, and Novo Nordisk still matter for Prothena
Explore how Prothena’s strategic collaborations with Roche, BMS, and Novo Nordisk could shape the future of Alzheimer’s drug development.